KaydedilenlerDerginizi ekleyin

Dergiler / Viral Hepatitis Journal / 2015 / Cilt: 21 - Sayı: 2

Yeni Hepatit C Tedavilerindeki Paradokslar: İnterferonsuz Sofosbuvir ve Ribavirin Kombinasyonu Genotip 1b Hepatit C Virüsü ile Enfekte Hastalarda Etkili mi?

Paradoxes in Novel Hepatitis C Therapies: Is Combination of Sofosbuvir and Ribavirin Without Interferon Effective in Genotype 1b Chronic HCV Patients?

Alpaslan TANOĞLU
Ergenekon KARAGÖZ
Hakan ERDEM
Vedat TURHAN
Asım ÜLÇAY
Sayfa
62–64
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

TANOĞLU, A., KARAGÖZ, E., ERDEM, H., TURHAN, V., ÜLÇAY, A. (2022). Yeni Hepatit C Tedavilerindeki Paradokslar: İnterferonsuz Sofosbuvir ve Ribavirin Kombinasyonu Genotip 1b Hepatit C Virüsü ile Enfekte Hastalarda Etkili mi?. Viral Hepatitis Journal, Cilt: 21 - Sayı: 2, 62–64. https://ajindex.com/articles/646412

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Ormeci N, Erdem H. Basic answers to complicated questions for the course of chronic hepatitis C treatment. Expert Rev Gastroenterol Hepatol. 2012; 6:371-382
  2. Erdem H, Akova M. Leading infectious diseases problems in Turkey. Clin Microbiol Infect. 2012;18:1056-1067
  3. Tosun S, Deveci S, Kaplan Y, Kasirga E. Should a booster dose be administered in children after mass immunization for hepatitis B? Hepat Mon. 2011; 11:440-444
  4. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013; 368:1907-1917
  5. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60:392-420
  6. Rapposelli D. Highlights from the Annual Meeting of the AASLD. Gastroenterol Hepatol (N Y). 2014; 10:194-195
  7. Kabakçı Alagöz G, Karataylı SC, Karataylı E, Celik E, Keskin O, Dinç B, Cınar K, Idilman R, Yurdaydın C, Bozdayı AM. Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: performance of phylogenetic analysis of the NS5B, E1, and 5’UTR regions in genotyping efficiency. Turk J Gastroenterol. 2014; 25:405-410
  8. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L,Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D; PHOTON-1 Investigators. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014; 312:353-361
  9. Lalezari JP, Nelson DR, Robert H. Once daily sofosbuvir plus ribavirin given for 12 or 24 weeks in treatment naïve patients with HCV infection:The Quantum Study. EASL 48th Annual Meeting, The Netherlands, Amsterdam 2013
  10. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015; 61:769-775
  11. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M,Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS rando